Dickson, PV; Nathwani, AC; Davidoff, AM; (2005) Delivery of antiangiogenic agents for cancer gene therapy. TECHNOL CANCER RES T , 4 (4) 331 - 341.
Full text not available from this repository.
The understanding that tumor growth and metastasis are angiogenesis dependent processes has led to interest in targeting tumor vasculature in anticancer therapy. Furthermore, recent insights into the molecular interactions that orchestrate physiologic and pathologlic angiogenesis have resulted in a variety of antiangiogenic strategies. A gene therapy-mediated approach for the delivery of antiangiogenic agents has several advantages, including the potential for sustained expression. However, the choice of angiogenesis inhibitor, method of gene delivery, and target/site for transgene expression are important variables to be considered when designing this approach. Here we review the major alternatives within each of these categories and provide illustrative examples of their use in preclinical models.
|Title:||Delivery of antiangiogenic agents for cancer gene therapy|
|Keywords:||cancer, antiangiogenesis, gene therapy, adeno-associated virus, review, ENDOTHELIAL GROWTH-FACTOR, INHIBITS TUMOR-GROWTH, ESTABLISHED INTRACRANIAL TUMORS, METASTATIC COLORECTAL-CANCER, LIVER-GENERATED EXPRESSION, BLOOD-VESSEL FORMATION, MARROW-DERIVED CELLS, WILD-TYPE P53, ANGIOGENESIS INHIBITOR, IN-VIVO|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > Wolfson Institute and Cancer Institute Administration > Cancer Institute > Research Department of Haematology|
Archive Staff Only: edit this record